Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Astec Lifesciences

Vijay Kedia’s Portfolio Sparkles As ‘Blue Chip’ & ‘Safe’ Stocks Notch Up Hefty Gains



The unique aspect of Vijay Kedia’s portfolio is that the stocks therein qualify as ‘blue chips’ or ‘safe’. Such stocks have the salutary habit of effortlessly notching up gains without putting the capital to any risk

Vijay Kedia’s Latest “Safe” Stock Pick Is A Blue Chip Potential Multi-Bagger: Expert



Vijay Kedia’s “safe” stock pick is a micro-cap which has been taken over by the blue-chip Godrej group. Godrej will transform the micro-cap into a powerhouse multi-bagger stock predicts Gaurav Parikh, a leading stock market expert

Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!